Source briefingSeptember 30, 2026Human Rights
Prenatal exposure to maternal depression and antidepressants and neurodevelopmental outcomes: A population cohort study

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.
What the source reports
by Saraid McIlvride, Neha Rao, Sarjit Singh, Scott M. Nelson, Jill P. Pell, Michael Fleming Background The long-term effects of antidepressant use in pregnancy on child neurodevelopment are unclear; meanwhile antidepressant use in pregnancy is increasing.
We aimed to clarify associations between prenatal maternal depression and/or antidepressant exposure and neurodevelopmental outcomes in school-age children. Methods and findings This population-wide cohort study included 167,447 children born in Wales, UK between 2009 and 2016, followed until 2022 (mean age 5.68 years) using linked primary…
Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.
Source & verification
Primary source: PLOS Medicine · September 29, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EMA/PE/0000181364
What is established The European Medicines Agency (EMA) has granted a decision regarding a paediatric investigation plan (PIP) for vosoritide as of 8 August…

EMA/PE/0000228795
Evidence Dossier: EMA Paediatric Investigation Plan for Ambrisentan/Tadalafil What is established The European Medicines Agency (EMA) has officially adopted a paediatric investigation plan (PIP)…

EMA/PE/0000261344
Evidence Dossier: EMA Decision on Colchicine Paediatric Investigation Plan (PIP) What is established On 8 August 2025, the European Medicines Agency (EMA) granted a…